immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl
Company profile
Ticker
IMRN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IMRN stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
23 Apr 24
6-K
Report of Foreign Private Issuer
15 Apr 24
6-K
Immuron Travelan® sales continued strong growth
10 Apr 24
6-K
Report of Foreign Private Issuer
14 Mar 24
6-K
Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
7 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Results for announcement to the market
28 Feb 24
6-K
Report of Foreign Private Issuer
21 Feb 24
6-K
Immuron achieves record Travelan® sales
13 Feb 24
6-K
Investor Webinar Presentation
9 Feb 24
Transcripts
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 23.82 mm |
Total shares | 11.79 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MS Morgan Stanley | 6.85 k | $13.83 mm |
BNP Paribas Arbitrage | 3.35 k | $6.76 mm |
Stephens Consulting | 1.50 k | $3.03 mm |
Global Wealth Management Investment Advisory | 100.00 | $202.00 k |
Proequities | 0.00 | $0.00 |
News
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Apr 24
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
10 Apr 24
Immuron Announced Travelan Sales Continued Strong Growth
9 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
Press releases
Immuron to host Live Virtual Event
15 Apr 24
Immuron Travelan® sales continued strong growth
10 Apr 24
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
7 Mar 24
Immuron Presentation Australian Biologics Festival 2024
21 Feb 24
Immuron achieves record Travelan® sales
13 Feb 24